PD-1 INHIBITOR
Clinical trials for PD-1 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PD-1 INHIBITOR trials appear
Sign up with your email to follow new studies for PD-1 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new combination of drugs for people with advanced esophageal squamous cell carcinoma (a type of throat cancer). The three drugs include a targeted therapy (becotatug vedotin), an immunotherapy (tislelizumab), and standard chemotherapy. The goal is to see if thi…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy aims to shrink rectal tumors without removing lymph nodes
Disease control Not yet recruitingThis study tests whether a short course of radiation that spares the lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), can completely eliminate rectal cancer before surgery. It includes 44 adults with stage II-III rectal cancer. The goal is to see if this approach …
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 08, 2026 12:02 UTC